News

On September 10, 2024, Ribocure Pharmaceuticals AB and Suzhou Ribo Life Science Ltd (Ribo) received authorization from the Swedish Medicinal

We thank the European Society of Cardiology #ESC Congress, session chairs, and all participants in the session for the opportunity

On May 27, 2024, Ribocure Pharmaceuticals AB and Suzhou Ribo Life Science Ltd (Ribo) received authorization from the Swedish Medicinal

Today we highlight the Clinical Trials Day and the importance of clinical research at Ribocure Pharmaceuticals and Ribocure Clinic. Ribocure

Ribocure Pharmaceuticals/Suzhou Ribo Life Science Co. Ltd. (“Ribo”) announce Notice of Allowance issued respectively by US Patent Office and European

On April 10, 2024, Ribo and Ribocure announce the completion of enrolment and dosing of the Ph1 clinical trial with

Ribocure Pharmaceuticals AB announces EMA authorisation to proceed with a Phase II clinical trial in Sweden. The trial will evaluate

Ribocure Pharmaceuticals AB is a clinical stage biotech company developing oligonucleotide-based therapeutics (siRNA). Across the globe, chronic kidney disease (CKD) affects

Ribocure Pharmaceuticals AB is a clinical stage biotech company developing oligonucleotide-based therapeutics (siRNA). Our primary focus lies in addressing unmet

Mölndal, Sweden, Kunshan, China and Ingelheim, Germany – 3 January 2024 Suzhou Ribo Life Science Co. Ltd. and Ribocure Pharmaceuticals

Our CEO has been portrayed in GoCo news. Here he shared his views on how productive collaboration between industry, academia

With the ambition to become the leading clinical oligonucleotide research company in Sweden, Ribocure Pharmaceuticals AB established Ribocure Clinic, with

John Taylor has joined Ribocure Pharmaceuticals AB as Vice President and Head of Global Business Development. John will lead the

Suzhou Ribo Life Science (Ribo) and Ribocure Pharmaceuticals (Ribocure) presented new data from three projects from its cardiovascular pipeline at

Thanks EASL for a great meeting and also the opportunity to simultaneously show data from our HBV program, both with

We arranged our inauguration ceremony together with both friends and colleagues from academia and industry, as well as many persons

Li-ming Gan, CEO at Ribocure Pharmaceuticals, is for the first time showing our preclinical PoC data at the EASL meeting

Ribocure Pharmaceuticals AB receives Authorisation for a Phase II clinical trial to evaluate efficacy and safety of its novel siRNA

In June we move into the entire fifth floor of the GoCo Clinic building and established a unique “from bench-to-bed”

GoCo House Lunch Launch took place and we were there from Ribocure Pharmaceuticals to meet our future neighbours and potential

World’s first siRNA-based FXI silencing agent enters clinical development – an important step toward a new generation of anti-thrombotic therapies

Ribocure participated in The Innovative Ecosystem at GoCo Arena event and pitched our vision and aims in just 3 minutes.

Visit at GoCo and Gothenburg by one of the founders, Dr Hongyan Zhang, from the parent comany. Impressed and inspired

First tour at the future office. A near 1000 sqm facility with R&D, lab and clinical trail unit will be

Ribocure Pharmaceuticals AB establishes in GoCo Clinic- putting Sweden in the spotlight within oligonucleotide therapeutics GoCo Health Innovation City can